FEATURED APPLICATION CONTENT

• How Lipid Nanoparticles Enable Next-Gen Delivery

  Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.

• Why Biopharma Breakthroughs Aren't Moving The Market

  Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.

• Optimization And Scale-Up Of A Plasmid DNA Production Process

  Optimizing pDNA production in E. coli requires strategic media selection and scale-up planning. Explore a study that identifies ideal conditions for high-yield manufacturing.

• Overcoming Unique Client Challenges With A Strong Collaborative Partnership

  Through close collaboration, proactive communication, and agile project management, our partnership accelerated an oncology program and helped overcome complex preclinical hurdles.

• BxPC-3: Evaluating Responses To Standard Therapeutic Agents

  Review multiple studies utilizing the BxPC-3 human pancreatic cancer model in subcutaneous (SC) NSG and NSG-dKO mouse models, evaluating a range of standard agents, vehicles, and delivery methods.

• A Risk-Based Approach To Plasmid DNA And mRNA Process Development

  Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

• Preclinical Technique To Assess Targeted Therapies For Primary, Metastatic NSCLC

  To enable comprehensive evaluation of therapies targeting both primary and metastatic tumors, we've developed dual-disease xenograft models using bioluminescence imaging (BLI).

• Characterize Your PROTAC Hook Effect With Flexible In-Solution Affinity Measurements

  Characterizing the PROTAC hook effect is crucial for selecting candidates with enhanced cooperativity. Gain confidence with flexible, in-solution affinity measurements that reveal key biophysical parameters and align with established three-component binding models.

• Aggregation In Antibody-Drug Conjugates: Causes And Mitigation

  Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.

• Time To Intensify: Taking mAb Manufacturing To The Next Level

  Explore how process intensification can revolutionize monoclonal antibody manufacturing to boost productivity, cut costs, and enhance sustainability with scalable strategies and real-world results.

• Cell Line Development For Bispecific Antibodies

  See how the recently described cell line development paradigm shift, enabled by the Leap-In transposon platform, can extend to the development of bispecific monoclonal antibody-producing cell substrates.

• Zero To Final Fill: How HUGEL Implemented Its First Single-Use Lines

  As regulations tighten, biomanufacturers are adopting single-use tech to boost compliance, reduce labor, and streamline fill-finish operations from the ground up.